Oncology

Genetic testing for hereditary and somatic cancers can provide life-changing results in affected patients and their relatives, accompanied by potential actionable steps for genetic-related cancers. With many different applications of genetic testing to detect and care for cancer, we can guide you in selecting the right options to enhance the treatment of your patients suffering from hereditary cancers. Having identified genetic variants associated with oncological diseases in more than 200 different genes, we can provide a comprehensive range to foster cancer diagnosis, prognosis, treatment selection, and monitoring.

Order on CentoPortal

BRCA1, BRCA2

Breast cancer is the most common type of cancer in woman constituting around 25% of all females cases. Mutations in BRCA1 and BRCA2 can increase the risk of developing cancer.

No. of genes: 2
TAT: 15 days
Coverage: ≥99.50% ≥20x

Order now Sample Requirements

BRCA1, BRCA2 Plus

No. of genes: 2
TAT: 15 days
Coverage: ≥99.50% ≥20x
Details:
NGS including CNV analysis

Order now Sample Requirements

BRCA1, BRCA2 Combi

No. of genes: 2
TAT: 15 days
Coverage: ≥99.50% ≥20x
Details:
MLPA: BRCA1, BRCA2

Order now Sample Requirements

BRCA1, BRCA2 Somatic

No. of genes: 2
TAT: 10 days

Order now Sample Requirements

COMMON SYNDROMES AND DISORDERS COVERED
  • Breast cancer

Available Downloads

CENTOGENE Hereditary Cancers Productsheet English PDF

Hereditary Cancer Panels – Product Sheet

Genetic testing for an improved prognosis

CENTOGENE BRCA1/2 Broschure Breast Cancer Testing

BRCA1/ BRCA2 Brochure

Think about tomorrow, today – Breast cancer testing

CentoBreast®

CentoBreast® detects mutations in the BRCA1 and BRCA2 genes, which are the most common hereditary causes for breast cancer. In addition, our panel includes other genes such as ATM, BRIP1, CHEK2, PALB2, RAD51, etc. which have also been associated with increased cancer risk. Breast cancer is one of the most common cancers in the world affecting ~12.5% of women during their lifetime, with 5–10% of these patients having a hereditary form.

No. of genes: 30
TAT: 15 days
Coverage: ≥99.50% ≥20x
Details:
NGS including CNV analysis

Order now Sample Requirements

COMMON SYNDROMES AND DISORDERS COVERED
  • Breast cancer
  • Ovarian cancer

Available Downloads

CENTOGENE CentoBreast Brochure English PDF

CentoBreast Brochure

Knowledge today. Action tomorrow.

CENTOGENE Hereditary Cancers Productsheet English PDF

Hereditary Cancer Panels – Product Sheet

Genetic testing for an improved prognosis

CentoCancer®

Each gene in CentoCancer has been carefully selected based on its risk potential in the development of one or more of the following cancers: breast, ovarian, colorectal, gastric, thyroid, endometrial, pancreatic, melanoma, renal, and prostate. This panel is appropiate for patients with positive personal history of early-onset cancer, rare cancer, bilateral cancer, or multiple primary cancers.

No. of genes: 70
TAT: 15 days
Coverage: 99.50% 20x
Details:
NGS including CNV analysis

Order now Sample Requirements

COMMON SYNDROMES AND DISORDERS COVERED
  • Breast cancer
  • Colorectal cancer
  • Endometrial cancer
  • Familial adenomatous polyposis
  • Gastric cancer
  • Gastrointestinal stromal tumor
  • Melanoma
  • Ovarian cancer
  • Pancreatic cancer
  • Prostate cancer
  • Renal cancer
  • Skin cancer
  • Thyroid cancer
  • Uterine cancer

Available Downloads

CENTOGENE Hereditary Cancers Productsheet English PDF

Hereditary Cancer Panels – Product Sheet

Genetic testing for an improved prognosis

CENTOGENE CentoCancer Brochure English PDF

CentoCancer Brochure

Strive for the complete information

CentoCancer comprehensive

CentoCancer comprehensive is our most extensive cancer panel, covering a large number of cancer-associated genes. Each gene in this panel has been carefully selected based on its risk potential in the development of one or more of the following cancers: breast, ovarian, colorectal, gastric, thyroid, endometrial, pancreatic, melanoma, renal, and prostate, among others.

No. of genes: 110
TAT: 15 days
Coverage: ≥99.00% ≥20x
Details:
NGS including CNV analysis

Order now Sample Requirements

COMMON SYNDROMES AND DISORDERS COVERED
  • Beckwith-Wiedemann syndrome
  • Breast cancer
  • Colorectal cancer
  • Endometrial cancer
  • Familial adenomatous polyposis
  • Gastric cancer
  • Gastrointestinal stromal tumor
  • Hereditary Paraganglioma/ Pheochromocytoma
  • Melanoma
  • Ovarian cancer
  • Pancreatic cancer
  • Paragangliomas/Pheochromocytoma/
  • Gastrointestinal stromal
  • Prostate cancer
  • Renal cancer
  • Retinoblastoma
  • Rothmund-Thomson syndrome (Type 2)
  • Skin cancer
  • Thyroid cancer
  • Uterine cancer

Available Downloads

CENTOGENE Hereditary Cancers Productsheet English PDF

Hereditary Cancer Panels – Product Sheet

Genetic testing for an improved prognosis

CentoCancer® Pediatric

Cancer occurs in people of all ages, with some being nearly exclusively tied to childhood. CentoCancer Pediatric is our comprehensive solution to detect genes associated with pediatric cancer. The gene list has been carefully curated by internal and external experts to cover the most common forms of pediatric cancer. Germline mutations identified by these panel will help to define prognosis, differentiate patient/family risk, and guide treatment decisions. Spotting cancer early increases the chances of survival.

No. of genes: 97
TAT: 15 days
Coverage: ≥99.00% 20x
Details: NGS including CNV analysis

Order now Sample Requirements 

COMMON SYNDROMES AND DISORDERS COVERED
  • Leukemia
  • Malignant brain tumors
  • Lymphomas
  • Bone cancer
  • Neuroblastoma
  • Wilms tumor
  • Rhabdomyosarcoma

CentoColon

CentoColon detects genes that are associated with colon, pancreatic, and gastric cancer.

No. of genes: 33
TAT: 15 days
Coverage: ≥99.50% ≥20x
Details:
NGS including CNV analysis

Order now Sample Requirements

COMMON SYNDROMES AND DISORDERS COVERED
  • Colorectal cancer
  • Familial adenomatous polyposis
  • Gastric cancer
  • Hereditary nonpolyposis colorectal cancer
  • Pancreatic cancer

Available Downloads

CENTOGENE Hereditary Cancers Productsheet English PDF

Hereditary Cancer Panels – Product Sheet

Genetic testing for an improved prognosis

Myeloid tumor panel

Our myeloid tumor panel targets important regions within 35 genes that are frequently mutated in myeloid malignancies. Myeloid malignancies are clonal diseases of hematopoietic progenitor cells. Myeloid tumors represent the fourth most frequently diagnosed cancer in economically developed countries. The majority of myeloid tumors contain high numbers of somatic mutations, which are genetic changes that are not inherited but created within the tumor itself. Unlike inherited “germline” mutations, these somatic mutations are not transmitted to offspring. Somatic mutations significantly contribute to the pathogenesis, progression, and prognosis of myeloid malignancies.

No. of genes: 35
TAT: 10 days
Coverage: ≥97.00% ≥200x

Order now Sample Requirements

COMMON SYNDROMES AND DISORDERS COVERED
  • Acute myeloid leukemia
  • Chronic myeloid leukemia
  • Chronic myelomonocytic leukemia
  • Juvenile myelomonocytic leukemia
  • Myelodysplastic syndrome
  • Myeloid tumor
  • Myeloproliferative neoplasms

Available Downloads

CENTOGENE Myeloid Productsheet English PDF

Myeloid Tumor Panel – Product Sheet

The targeted approach to detecting myeloid malignancies

Solid tumor panel

Our solid tumor panel provides full sequencing of 106 selected cancer-associated genes as well as the hotspot analysis of relevant cancer regions in 43 genes. It detects over 5,000 validated oncogenic variants and includes the latest evidence-based variants associated with treatment decisions in solid tumors. The panel has more than 25 genes with approved targeted therapies or those that are being currently tested in clinical trials. Furthermore, somatic variants with an impact on prognosis of the individual tumor or on the efficacy of standard anti-tumor therapy are captured. It covers more than 100 different types of somatic cancers, including adrenal, colon, hepatic, prostate, renal, skin, testicular, thyroid, glioma, esophageal, endometrial, and breast cancer, among others. The panel provides a better understanding of tumor behavior as well as its likelihood to respond to a treatment, contributing to tailored medicine for the patient, thus frequently leading to a better outcome or reduced adverse effects.

No. of genes: 149
TAT: 10 days
Coverage: ≥97.00% ≥200x
Details:
Hotspot analysis (somatic hotspot analysis): ALK, ARAF, AXL, BTK, CBL, CCND1, CDK6, ERCC2, ESR1, FLT3, FOXL2, GATA2, H3-3A, H3C2, JAK1, JAK2, JAK3, KNSTRN, MAGOH, MAP2K4, MAPK1, MAX, MDM4, MED12, MYC, MYCN, MYD88, NTRK1, NTRK2, PDGFRB, PIK3CB, PPP2R1A, RAC1, RAF1, RHEB, RHOA, ROS1, SF3B1, STAT3, TERT, TOP1, U2AF1, XPO1

Order now Sample Requirements

COMMON SYNDROMES AND DISORDERS COVERED
  • Adrenal cancer
  • Biliary tract cancer
  • Bone marrow cancer
  • Breast cancer
  • Colon cancer
  • Endometrial cancer
  • Esophageal cancer
  • Gastrointestinal stromal tumor
  • Glioma
  • Hepatic cancer
  • Lung cancer
  • Lymphoma cancer
  • Meningioma
  • Ovarian cancer
  • Pancreatic cancer
  • Prostate cancer
  • Renal cancer
  • Skin cancer
  • Testicular cancer
  • Thyroid cancer

Available Downloads

CENTOGENE Productsheet Solid Tumor Panel English

Solid Tumor Panel – Product Sheet

Providing knowledge to battle cancer

Visit Our Online Ordering Portal

CentoPortal® is a user-friendly, online, web-based ordering portal designed to assist you at every step of processing your patients' samples.

Go to CentoPortal

CENTOGENE CentoPortal Logo